Roche's GLP-1 Drug for Weight Management Clears Clinical Trial Approval in China

Stock News

May 09

Recently, the CDE website indicated that Roche Holding Ltd's (RHHBY.US) RO7795068 injection has received approval for clinical trials. The drug is intended for the long-term weight management of adult patients with obesity or who are overweight, in conjunction with dietary control and increased physical activity. Information shows that RO7795068 is a GLP-1R/GIPR dual agonist developed by Carmot. In December 2023, Roche acquired Carmot for $3.1 billion, securing this product. It is reported that the obesity indication for RO7795068 has already advanced to Phase III clinical trials overseas. Phase II results demonstrated that weekly subcutaneous injections of RO7795068 (with doses gradually increased to 24mg) led to a significant weight reduction of 22.5% (estimated efficacy value) in patients, with no weight loss plateau reached at 48 weeks.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1179377515"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179377515\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179377515?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-09 20:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179377515","market":"us","top_or_hot":-1,"title":"Roche's GLP-1 Drug for Weight Management Clears Clinical Trial Approval in China","media":"Stock News","content":"<p>Recently, the CDE website indicated that Roche Holding Ltd's (RHHBY.US) RO7795068 injection has received approval for clinical trials. The drug is intended for the long-term weight management of adult patients with obesity or who are overweight, in conjunction with dietary control and increased physical activity. Information shows that RO7795068 is a GLP-1R/GIPR dual agonist developed by Carmot. In December 2023, Roche acquired Carmot for $3.1 billion, securing this product. It is reported that the obesity indication for RO7795068 has already advanced to Phase III clinical trials overseas. Phase II results demonstrated that weekly subcutaneous injections of RO7795068 (with doses gradually increased to 24mg) led to a significant weight reduction of 22.5% (estimated efficacy value) in patients, with no weight loss plateau reached at 48 weeks.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche's GLP-1 Drug for Weight Management Clears Clinical Trial Approval in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche's GLP-1 Drug for Weight Management Clears Clinical Trial Approval in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-09 20:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Recently, the CDE website indicated that Roche Holding Ltd's (RHHBY.US) RO7795068 injection has received approval for clinical trials. The drug is intended for the long-term weight management of adult patients with obesity or who are overweight, in conjunction with dietary control and increased physical activity. Information shows that RO7795068 is a GLP-1R/GIPR dual agonist developed by Carmot. In December 2023, Roche acquired Carmot for $3.1 billion, securing this product. It is reported that the obesity indication for RO7795068 has already advanced to Phase III clinical trials overseas. Phase II results demonstrated that weekly subcutaneous injections of RO7795068 (with doses gradually increased to 24mg) led to a significant weight reduction of 22.5% (estimated efficacy value) in patients, with no weight loss plateau reached at 48 weeks.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLP","symbol_name":"Global Partners Lp","start_time":0,"source_url":"","article_id":"1179377515","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179377515","pubTimestamp":1778328631,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Recently, the CDE website indicated that Roche Holding Ltd's (RHHBY.US) RO7795068 injection has received approval for clinical trials. The drug is intended for the long-term weight management of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GLP":"Global Partners Lp","BK4144":"石油与天然气的储存和运输","BK4007":"制药","03165":"华夏欧优股对冲","RHHBY":"罗氏控股","BK4590":"PTP"},"translate_title":"罗氏用于体重管理的GLP-1药物在中国通过临床试验批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":1,"RHHBY":1,"GLP":1},"content_text":"Recently, the CDE website indicated that Roche Holding Ltd's (RHHBY.US) RO7795068 injection has received approval for clinical trials. The drug is intended for the long-term weight management of adult patients with obesity or who are overweight, in conjunction with dietary control and increased physical activity. Information shows that RO7795068 is a GLP-1R/GIPR dual agonist developed by Carmot. In December 2023, Roche acquired Carmot for $3.1 billion, securing this product. It is reported that the obesity indication for RO7795068 has already advanced to Phase III clinical trials overseas. Phase II results demonstrated that weekly subcutaneous injections of RO7795068 (with doses gradually increased to 24mg) led to a significant weight reduction of 22.5% (estimated efficacy value) in patients, with no weight loss plateau reached at 48 weeks.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}